Market Research Logo

Celiac Disease - Pipeline Review, H2 2015

Celiac Disease - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Celiac Disease - Pipeline Review, H2 2015’, provides an overview of the Celiac Disease’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Celiac Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Celiac Disease and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Celiac Disease
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Celiac Disease and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Celiac Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Celiac Disease pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Celiac Disease
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Celiac Disease pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Celiac Disease Overview
Therapeutics Development
Pipeline Products for Celiac Disease - Overview
Pipeline Products for Celiac Disease - Comparative Analysis
Celiac Disease - Therapeutics under Development by Companies
Celiac Disease - Therapeutics under Investigation by Universities/Institutes
Celiac Disease - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Celiac Disease - Products under Development by Companies
Celiac Disease - Products under Investigation by Universities/Institutes
Celiac Disease - Companies Involved in Therapeutics Development
Alba Therapeutics Corporation
Alvine Pharmaceuticals, Inc.
Amgen Inc.
Amyra Biotech AG
Avaxia Biologics, Inc.
Calypso Biotech SA
enGene, Inc
Glenmark Pharmaceuticals Ltd.
ImmusanT, Inc.
Intrexon Corporation
Provid Pharmaceuticals, Inc.
Selecta Biosciences, Inc.
Sitari Pharmaceuticals, Inc.
Zedira GmbH
Celiac Disease - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles AMG-714 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AVX-176 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Biologic to Antagonize HLA-DQ2 for Celiac Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Biologic to Target Gluten and IL-10 for Celiac Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Biologics to Inhibit Transglutaminase 2 for Celiac Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CALY-002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Enzyme for Celiac Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Enzymes for Celiac Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ERW-1041E - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GBR-830 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
larazotide acetate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
latiglutenase - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody to Inhibit IL-2 and IL-15 for Oncology and Gastrointestinal Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nexvax-2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nexvax-3 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oligonucleotides for Celiac Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Peptide for Celiac Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein for Celiac Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Synthetic Peptide to Inhibit DQ2/DQ8 for Celiac Disease and Type 1 Diabetes - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vaccine for Celiac Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ZED-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ZED-1098 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ZED-1219 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ZED-1227 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ZED-754 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Celiac Disease - Recent Pipeline Updates
Celiac Disease - Dormant Projects
Celiac Disease - Product Development Milestones
Featured News & Press Releases
Sep 23, 2015: Celimmune to Present Overview of Non-Dietary Celiac Disease Therapies in Development at Annual Celiac Support Association Meeting
Sep 03, 2015: Glenmark's Novel Monoclonal Antibody GBR 830 to Enter Phase 2 Clinical Studies in Atopic Dermatitis and Celiac Disease in US and Europe
Jun 22, 2015: Celimmune to Present Experimental Anti3IL315 Antibody AMG!714 at 16th International Coeliac Disease Symposium
Jun 22, 2015: Cour Pharmaceuticals Releases Data on Potential Breakthrough Treatment for Celiac Disease
Nov 19, 2014: ImmusanT’s Immunotherapy for Celiac Disease, Nexvax2, Selected as One of Informa’s Top 10 Autoimmune/Anti-Inflammatory Projects to Watch
Jun 12, 2014: Potential New Treatment May Protect Celiac Patients from Gluten-Induced Injury
Feb 11, 2014: Alba Therapeutics Announces Positive Results of Phase IIb Trial in Celiac Disease
Oct 29, 2013: Alvine Pharmaceuticals Doses First Patient in Phase 2b Trial for ALV003 in Celiac Disease
Aug 06, 2013: ImmusanT Initiates Study at Joslin Diabetes Center to Investigate Relationship Between Celiac Disease and Type 1 Diabetes
Apr 19, 2013: ImmusanT’s Epitope-specific Immunotherapy For Celiac Disease Informs Potential Of Vaccines Against Other Autoimmune Diseases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Celiac Disease, H2 2015
Number of Products under Development for Celiac Disease - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Celiac Disease - Pipeline by Alba Therapeutics Corporation, H2 2015
Celiac Disease - Pipeline by Alvine Pharmaceuticals, Inc., H2 2015
Celiac Disease - Pipeline by Amgen Inc., H2 2015
Celiac Disease - Pipeline by Amyra Biotech AG, H2 2015
Celiac Disease - Pipeline by Avaxia Biologics, Inc., H2 2015
Celiac Disease - Pipeline by Calypso Biotech SA, H2 2015
Celiac Disease - Pipeline by enGene, Inc, H2 2015
Celiac Disease - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2015
Celiac Disease - Pipeline by ImmusanT, Inc., H2 2015
Celiac Disease - Pipeline by Intrexon Corporation, H2 2015
Celiac Disease - Pipeline by Provid Pharmaceuticals, Inc., H2 2015
Celiac Disease - Pipeline by Selecta Biosciences, Inc., H2 2015
Celiac Disease - Pipeline by Sitari Pharmaceuticals, Inc., H2 2015
Celiac Disease - Pipeline by Zedira GmbH, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Celiac Disease Therapeutics - Recent Pipeline Updates, H2 2015
Celiac Disease - Dormant Projects, H2 2015
List of Figures
Number of Products under Development for Celiac Disease, H2 2015
Number of Products under Development for Celiac Disease - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Targets, H2 2015
Number of Products by Stage and Targets, H2 2015
Number of Products by Mechanism of Actions, H2 2015
Number of Products by Stage and Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report